Viropro, Inc. engages in the development, manufacture and sale of biopharmaceutical products. The company is headquartered in Irvine, California and currently employs 34 full-time employees. The company went IPO on 2001-06-21. The firm conducts operations primarily through its subsidiary, Alpha Biologics Sdn Bhd (Alpha) located in Penang, Malaysia. The firm intends to offer solution to the biopharma industry from drug concept through to product manufacturing. The Alpha facility consists of approximately 50,000 square feet of research and production space. The Alpha facility is designed to support the scale-up and manufacture of monoclonal antibodies.
최신 재무제표(Form-10K)에 따르면, Viropro Inc의 총 자산은 $2이며, 순손실입니다.
VPRO의 주요 재무 비율은 무엇인가요?
Viropro Inc의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Viropro Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Viropro Inc 주요 수익원은 Real Estate Brokerage Services (Residential)이며, 최신 수익 발표에서 수익은 57,024,911입니다. 지역별로는 United States이 Viropro Inc의 주요 시장이며, 수익은 69,448,786입니다.